May 31, 2018 10:04 AM EDT

Astellas, FibroGen hit primary endpoint in PhIII; vTv inks PDE4 inhibitor deal with Newsoara

Brittany Meiling

→ Astellas and FibroGen are reporting that their fourth late-stage study of roxadustat hit the primary endpoint for anemia in patients with CKD. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Astellas, FibroGen hit primary endpoint in PhIII; vTv inks PDE4 inhibitor deal with Newsoara

Brittany Meiling

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

FDA approves Ionis’ treatment for a rare metabolic disorder

Astel­las, Fi­bro­Gen hit pri­ma­ry end­point in PhI­II; vTv inks PDE4 in­hibitor deal with New­soara

Brittany Meiling

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Astellas, FibroGen hit primary endpoint in PhIII; vTv inks PDE4 inhibitor deal with Newsoara

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

FDA approves Ionis’ treatment for a rare metabolic disorder